交晨生物医药技术

Jiaochen Biomedical is a Shanghai-based biotechnology company specializing in the development of novel therapeutics for neurodegenerative and metabolic diseases through its proprietary Autophagy-Tethering Compounds (ATTEC) platform. The company's technology utilizes small molecules to selectively tether pathogenic proteins or organelles to autophagosomes, facilitating their degradation via the autophagy-lysosome pathway. This innovative approach allows for the targeting of traditionally undruggable proteins, such as mutant Huntingtin and Tau, which are central to diseases like Huntington's and Alzheimer's. Founded by a scientific team from Fudan University, Jiaochen is a pioneer in the field of targeted protein degradation beyond the ubiquitin-proteasome system. The company has attracted significant investment from leading venture capital firms to advance its pre-clinical pipeline toward human clinical trials.